Li Ning, Junshi Biosciences CEO
Junshi Biosciences touts lung cancer data as it looks to expand PD-1 label in China again
In a bid to get another PD-1 regimen approved in China, Junshi Biosciences has spelled out Phase III data showing that its drug cut the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
